Abstract: The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by an infectious agents in a patient, comprising administering an effective amount of a C5 inhibitor, such as eculizumab or an eculizumab variant, to the patient.

Abstract: A gun mounting device comprising a gun rest bridge and a C-clamp. The gun rest bridge comprising a central beam horizontally extending between a pair of cradle bars, and a pair of cradle rests atop said pair of cradle bars, where said pair of cradle rests are U-shaped to accept a barrel of a gun. The C-clamp attached beneath said central beam, where said C-clamp comprises a pair of arms to receive a support item into a central portion of said C-clamp, where said pair of arms include a first arm and a second arm; a clamp rod threaded through said first arm; a turning handle connected to said clamp rod; and a grip pad connected to said clamp rod opposite to said turning handle wherein said turning handle rotates to move said grip pad towards said second arm to secure said C-clamp against said support item.

Abstract: The present invention relates to novel synthetic muc-1 peptides and muc-1-like analogs including at least two 20-amino acid tandem repeats of muc-1, which synthetic muc-1 and muc-1-like peptides are capable of attaining native conformation in the absence of glycosylation. The invention also relates to methods of producing the peptides. The invention further relates to uses of the peptides, such as for vaccines and diagnostic testing.

Abstract: The present invention relates to novel synthetic muc-1 peptides and muc-1 analogs comprising at least two 20-amino acid tandem repeats of muc-1, wherein said synthetic muc-1 peptide is capable of attaining native conformation in the absence of glycosylation. The invention also relates methods of producing the peptides. The invention further relates to uses of the peptides, such as for vaccines and diagnostic testing.

Abstract: The present invention discloses peptide vaccines and associated methods for protection against feline leukemia virus (FeLV). The synthetic peptides of the present invention retain their secondary structural identity, stimulate antibodies reactive to the whole virus and elicit a cellular response in vaccinations. These synthetic peptides are inexpensive to produce, stable and permit easy differentiation of vaccinated versus FeLV-infected cats.